Xolair Uses: What It Treats and How It Works

What Xolair Is and How It Works

Xolair (omalizumab) is a prescription monoclonal antibody that targets immunoglobulin E, the antibody involved in allergic responses. By binding to IgE, it reduces the allergic cascade that drives symptoms in several conditions. It is given as an injection, typically every two or four weeks, and is reserved for patients whose disease remains inadequately controlled despite standard therapies.

Allergic Asthma

The primary xolair uses include moderate-to-severe persistent allergic asthma in patients aged six and older who have a positive skin test or in-vitro reactivity to a perennial allergen and remain symptomatic on inhaled corticosteroids. Treatment can reduce exacerbations, lower emergency department visits, and improve lung function and daytime symptoms. It is not a rescue medication and does not replace inhaled corticosteroids; it is an add-on biologic for patients who need additional control.

Chronic Idiopathic Urticaria

Xolair is also approved for chronic spontaneous urticaria, previously called chronic idiopathic urticaria, in patients who remain symptomatic despite H1 antihistamine treatment. In this use, it can significantly reduce itch, the number of hives, and the impact on sleep and daily life. Improvement often appears within the first few weeks of treatment, though full benefit may take longer to become clear.

Nasal Polyps

In adults with nasal polyposis, particularly when polyps are severe and not adequately controlled by surgery or nasal corticosteroids alone, xolair uses include reducing polyp size, nasal congestion, and the need for additional steroids or repeat surgery. The effect on polyps appears linked to dampening the allergic and inflammatory pathways that drive polyp growth.

Who Is a Candidate

Xolair is generally considered when symptoms remain uncontrolled despite optimized standard therapy. For asthma, this usually means persistent symptoms or frequent exacerbations on moderate-to-high-dose inhaled corticosteroids, often with a long-acting bronchodilator. For urticaria, it is for patients who continue to have breakouts despite regular antihistamines. A clinician will confirm the diagnosis, assess severity, and often check IgE levels and body weight, since dosing depends on both.

Dosing and Administration

Xolair is administered by subcutaneous injection in a healthcare setting, initially under observation for anaphylaxis risk. The dose is determined by IgE level and body weight, and the interval is every two or four weeks. Patients should continue their baseline asthma or urticaria medications unless a clinician advises otherwise. Missing doses can reduce effectiveness, so maintaining the schedule is important.

Side Effects and Safety

The most serious risk is anaphylaxis, which can occur after injection and is why the first few doses are given in a monitored setting. Common side effects include injection-site reactions, joint pain, fatigue, and headache. Xolair may also increase the risk of certain cardiovascular or cerebrovascular events in patients with existing risk factors, though the exact relationship remains under study. Any history of allergic reactions to omalizumab or its components is a contraindication.

Practical Considerations

Because xolair uses are tied to measurable allergic pathways, it is most effective in patients with confirmed IgE-mediated disease. Treatment response can be assessed by symptom diaries, exacerbation rates, and quality-of-life measures over several months. Cost and access can be barriers, as it is a biologic requiring specialty pharmacy coordination and prior authorization. Patients should discuss with their clinician whether Xolair fits into their overall management plan, including what to expect in the first weeks and how to monitor progress.